The S Proteins of Human Coronavirus NL63 and Severe Acute Respiratory Syndrome Coronavirus Bind Overlapping Regions of ACE2
Overview
Authors
Affiliations
The cellular receptor for human coronavirus NL63 (HCoV-NL63), a group I coronavirus, is angiotensin-converting enzyme2 (ACE2). ACE2 is also the receptor for the SARS coronavirus (SARS-CoV), a group II coronavirus. Here we describe the ability of HCoV-NL63 to utilize a number of ACE2 variants previously characterized as SARS-CoV receptors. Several ACE2 variants that reduced SARS-CoV S-protein association similarly reduced that of HCoV-NL63, whereas alteration of a number of solvent-exposed ACE2 residues did not interfere with binding by either S protein. One notable exception is ACE2 residue 354, at the boundary of the SARS-CoV binding site, whose alteration markedly inhibited utilization by the HCoV-NL63 but not SARS-CoV S proteins. In addition, the SARS-CoV S-protein receptor-binding domain inhibited entry mediated by the HCoV-NL63 S protein. These studies indicate that HCoV-NL63, like SARS-CoV, associates region of human ACE2 that includes a key loop formed by beta-strands 4 and 5.
Structural proteins of human coronaviruses: what makes them different?.
Minigulov N, Boranbayev K, Bekbossynova A, Gadilgereyeva B, Filchakova O Front Cell Infect Microbiol. 2024; 14:1458383.
PMID: 39711780 PMC: 11659265. DOI: 10.3389/fcimb.2024.1458383.
COVID-19: An overview on possible transmission ways, sampling matrices and diagnosis.
Armani Khatibi E, Farshbaf Moghimi N, Rahimpour E Bioimpacts. 2024; 14(6):29968.
PMID: 39493896 PMC: 11530968. DOI: 10.34172/bi.2024.29968.
Penney A, Ng C, Sands N, Gaikwad R, Akhter M Cureus. 2024; 16(9):e68900.
PMID: 39376831 PMC: 11458280. DOI: 10.7759/cureus.68900.
Unveiling the occurrence of COVID-19 in a diverse Bangladeshi population during the pandemic.
Hossain M, Mannan R, Islam S, Banu L, Jamee A, Hassan Z Front Public Health. 2024; 12:1363971.
PMID: 38883197 PMC: 11176491. DOI: 10.3389/fpubh.2024.1363971.
Stanley A, Aksyuk A, Wilkins D, Green J, Lan D, Shoemaker K Front Immunol. 2024; 15:1401728.
PMID: 38827749 PMC: 11143795. DOI: 10.3389/fimmu.2024.1401728.